P
Peter Blake
Researcher at The Royal Marsden NHS Foundation Trust
Publications - 55
Citations - 2626
Peter Blake is an academic researcher from The Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Radiation therapy & Brachytherapy. The author has an hindex of 25, co-authored 55 publications receiving 2509 citations.
Papers
More filters
Journal ArticleDOI
Mucinous Epithelial Ovarian Cancer: A Separate Entity Requiring Specific Treatment
Viviane Hess,Roger A'Hern,N. Nasiri,D. Michael King,Peter Blake,Desmond P.J. Barton,John H. Shepherd,Thomas Ind,J. E. Bridges,Kevin J. Harrington,Stanley B. Kaye,Martin Gore +11 more
TL;DR: Patients with advanced mEOC have a poorer response to platinum-based first-line chemotherapy compared with patients with other histologic subtypes of EOC, and their survival is worse, and specific alternative therapeutic approaches should be sought.
Journal ArticleDOI
Contribution of BRCA1 Mutations to Ovarian Cancer
John F. Stratton,Simon A. Gayther,Paul S. Russell,Jo Dearden,Martin Gore,Peter Blake,Doug Easton,Bruce A.J. Ponder +7 more
TL;DR: Assuming that the method has a sensitivity of 70 percent, mutations in BRCA1 occur in approximately 5 percent (95 percent confidence interval, 3 to 8 percent) of women in whom ovarian cancer is diagnosed before the age of 70 years.
Journal ArticleDOI
Natural history and prognosis of untreated stage I epithelial ovarian carcinoma.
F.Y. Ahmed,Eve Wiltshaw,Roger A'Hern,B Nicol,John H. Shepherd,Peter Blake,Cyril Fisher,M. E. Gore +7 more
TL;DR: This is an important series, as no patient received adjuvant therapy, and represents the natural history of surgically resected stage I EOC, and indicates the impact of pre-operative rupture remains unclear.
Journal ArticleDOI
How patients manage gastrointestinal symptoms after pelvic radiotherapy.
B. Gami,Kevin J. Harrington,Peter Blake,David P. Dearnaley,Diana Tait,John Davies,A. R. Norman,H. J. N. Andreyev +7 more
TL;DR: How frequently patients develop a permanent change in bowel habit after pelvic radiotherapy that affects their quality of life is not clear because the measures of gastrointestinal toxicity used in trials in the past have generally been inadequate.
Journal ArticleDOI
Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group
M. E. Gore,Paul N. Mainwaring,Roger A'Hern,V. Macfarlane,Maurice L. Slevin,Peter Harper,Richard Osborne,Janine Mansi,Peter Blake,Eve Wiltshaw,John H. Shepherd +10 more
TL;DR: Carboplatin offers an opportunity to intensify cisplatin therapy, but a greater than two-fold increase in dose-intensity probably needs to be achieved before significant effects on survival will be produced and hematologic support will be required.